Featured News
January 06, 2026
Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1
December 30, 2025
Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference
November 19, 2025
Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc
Our Commitment to Responsibility
At Alkermes, we are committed to making a difference not only in the lives of people living with complex psychiatric and neurological disorders, but also in the communities in which we live and work. We seek to operate our business ethically and grow our organization in a responsible and sustainable manner. Our most recent Corporate Responsibility Report details our efforts.
Our Stories
Each endeavor at Alkermes starts with collaboration and our shared commitment to make a difference for patients and our communities. These stories – which highlight our people, science and innovation, and leadership perspectives – showcase just a subset of what makes us proud to be part of Alkermes. Visit our full gallery of stories by clicking on the link below.
A Career Journey: 20 Years in IT Leadership
Tom Harvey reflects on twenty years of growth, friendship and the unique culture at Alkermes.
Building on Our Heritage
Craig Hopkinson reflects on Alkermes' efforts to leverage our deep neuroscience expertise to make a difference.
Alkermes Pathways Research Awards: Seven Years of Impact
Learn about the impact of the Pathways Research Awards program.
Media Resources
Company Description
Alkermes applies its deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. A fully-integrated, global biopharmaceutical company, headquartered in Ireland with U.S. locations in Massachusetts and Ohio, we seek to make a meaningful difference in the way people manage their diseases. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of innovative new medicines, including those for people with conditions that have traditionally been overlooked or stigmatized.
Follow us on our social channels
